APEIRON is a privately-held European biotech company based in the heart of Europe, in Vienna, Austria, focused on the discovery and development of novel cancer immunotherapies and respiratory treatments.
Our company has a well balanced portfolio with one product on the market and several promising products from clinical to pre-clinical stages. As for the product on the market, APEIRON received EU marketing approval for APN311 (Dinutuximab beta, Qarziba®) in May 2017 for the treatment of pediatric neuroblastoma patients. We out-licensed Qarziba® globally to EUSA Pharma Ltd, for which it holds exclusive rights to this product.
APEIRON’s key projects and technologies are bolstered by a strong patent portfolio with broad territorial coverage. Our development expertise is validated through partnerships with leading global pharmaceutical companies and academic institutions.
TechnologiesAI Companies (Drug Discovery)
Apeiron is targeting the cancer cell cycle with a portfolio of next generation CDK inhibitors and harnessing synthetic lethal interactions in anti-cancer drug discovery.
APEIRON is focused on developing therapies to effectively treat respiratory diseases and cancer. Our respiratory platform around ACE2 is specifically targeting COVID-19 as well as ARDS (Acute Respiratory Distress Syndrome) and ALI (Acute Lung Injury). Our immune-oncology pipeline concentrates on next-generation checkpoint inhibitor Cbl-b and novel IO targets to activate the patient’s immune system against various tumors.
No services posted yet